Teva Pharmaceutical Industries Limited (TEVA) is a global pharmaceutical company focused on generics, biosimilars, and branded central nervous system and respiratory medicines. The central $47 target used here is not a published consensus headline but the arithmetic mean of 11 recent, individually attributable targets, rounded from about $46.9. The range runs from $40 (Jefferies) to $55 (TD Cowen).
Recent actions show an upward bias. Barclays' Glen Santangelo raised his target from $42 to $47 in mid-October 2026, while J.P. Morgan's Chris Schott lifted his from $40 to a Street-high $50. Goldman Sachs (Salveen Richter) also maintained a $50 target, grounded in an EV/EBITDA (enterprise value to earnings before interest, taxes, depreciation, and amortization) framework. UBS moved to $48, Piper Sandler to $44, and newer initiations came in constructive: TD Cowen at $55, Oppenheimer at $50, and Leerink Partners at $45. Bank of America and Jefferies sit at the conservative end at $42 and $40.
The spread reflects different views on how much branded growth can offset persistent generic pressure, not a disagreement that the business is improving. Most analysts rate the stock Buy or Overweight, but a high target is not inherently more likely than a low one.
With shares near $42.09 and a 52-week range of roughly $20 to $42.59, the stock is trading near multi-year highs after a powerful recovery. Reaching $47 implies upside of roughly 12%, a modest move for a name that has already re-rated substantially. The forward P/E (price-to-earnings) of roughly 13 sits well below the trailing multiple above 60, reflecting expectations that profitability is still normalizing.
A path toward $47 would most likely depend on continued execution in AUSTEDO for tardive dyskinesia and Huntington's disease, AJOVY for migraine, and UZEDY for schizophrenia, together with a credible narrative around late-stage assets such as the anti-TL1A candidate duvakitug. Cost-reduction programs and debt management also matter, since the company's leverage remains a key valuation input.
The stock's move from a 52-week low near $20 to recent highs above $42 places it in a strong long-term uptrend, with the 50-day moving average above the 200-day average. The 52-week high near $42.59 is the immediate resistance level to clear, and a decisive move above it would open the path toward the $45 and $50 psychological levels. On the downside, the $40 round-number zone and the 50-day moving average near $38 represent notable support levels in a pullback.
Analyst price targets typically reflect a roughly 12-month horizon, though individual firms apply different valuation methods and timeframes. The next major catalyst is the third-quarter earnings report scheduled for early November 2026. Investors should watch revenue and guidance for AUSTEDO, AJOVY, and UZEDY, pipeline updates for duvakitug, generic pricing trends, and any further analyst target revisions or rating changes.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For those tracking names like TEVA, the tool offers a data-driven complement to traditional research.
The $47 central target is a rounded average of 11 verified analyst targets spanning $40 to $55, and it sits roughly 12% above the latest price. The balance of evidence is constructive, built on branded growth, pipeline catalysts, and improving profitability, but the wide target range shows analysts disagree on how much of that optimism is already priced in. Generic erosion, regulatory risk, and litigation remain real obstacles. Whether Teva reaches $47 will depend chiefly on execution in its branded portfolio and the outcome of upcoming pipeline and earnings events, and no analyst target should be read as a guarantee of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To TEVA | 1D Price Change % | ||
|---|---|---|---|---|
| TEVA | 100% | -0.14% | ||
| AMRX - TEVA | 39% Loosely correlated | -1.29% | ||
| VTRS - TEVA | 34% Loosely correlated | +1.59% | ||
| COLL - TEVA | 28% Poorly correlated | -0.25% | ||
| HROW - TEVA | 26% Poorly correlated | +0.74% | ||
| SNDL - TEVA | 26% Poorly correlated | +4.44% | ||
More | ||||
| Ticker / NAME | Correlation To TEVA | 1D Price Change % |
|---|---|---|
| TEVA | 100% | -0.14% |
| Pharmaceuticals: Generic industry (82 stocks) | -1% Poorly correlated | +0.95% |